Scinai Immunotherapeutics
SCNI
13 hedge funds and large institutions have $560K invested in Scinai Immunotherapeutics in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.31% less ownership
Funds ownership: 1.69% → 1.38% (-0.31%)
7% less funds holding
Funds holding: 14 → 13 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
37% less capital invested
Capital invested by funds: $891K → $560K (-$331K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$56.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$46.2K |
| 3 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
+$30.8K |
| 4 |
HF
HRT Financial
New York
|
+$10.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$259K |
| 2 |
Millennium Management
New York
|
-$33K |
| 3 |
Morgan Stanley
New York
|
-$15.4K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$14K |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.57K |
SCNI Hedge Fund Activity: Q3 2021 in Review
13 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2021, worth a combined $560K — down 37% from $891K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $56.5K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $259K sold.
- 13 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2021, down from 14 in Q2 2021.
- Funds reported $560K of Scinai Immunotherapeutics stock for Q3 2021, down 37% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q3 2021 and 3 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q3 2021 was Virtu Financial, an estimated $56.5K added.
- The largest Scinai Immunotherapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $259K sold.
Based on aggregated 13F filings for Q3 2021.